Introduction
The present decade has witnessed an unprecedented mobilization of resources and engagement of governments and international and nongovernmental organizations for the expansion of access to antiretroviral therapy (ART) for HIV-infected people in low-and middle-income settings [1] . Combination ART has become the standard of HIV care around the world and produces comparable clinical results in both developed and developing countries [2] [3] [4] [5] . Despite the dramatic rise in global funding for HIV/AIDS and reductions in drug prices [6] , many resource-limited countries will have difficulty sustaining long-term therapy due to logistical and political barriers and, more importantly, substantial resource constraints.
Among patients who are able to initiate ART and reach treatment goals, one main concern is the frequency with which costly laboratory tests should be administered to monitor treatment efficacy and toxicity, as well as the choice of subsequent therapeutic regimens, in which most drugs are still patented and thus very costly compared with first-line regimens [7] . This situation suggests a growing trade-off between program coverage and treatment quality objectives in many resource-limited settings.
In the face of economic constraints, it is critically important to evaluate how best to utilize available resources [8, 9] . Cost-effectiveness analysis (CEA) is a well established methodology for understanding, prioritizing and optimizing healthcare services. By comparing treatment alternatives in light of their relative advantages and costs, CEA can serve as one key element to inform HIV/AIDS treatment guidelines [10] .
In this article, we review the growing number of CEAs of HIV treatment in resource-limited settings that use either cohort studies or mathematical models. Several studies conducted in resource-limited settings have already shown that a single line of ART is cost effective and very cost effective in certain settings compared with no ART [10] [11] [12] [13] 14 , [16 ] . First, we describe studies that assess the impact of earlier compared with deferred ART initiation in resource-limited settings, as recent trials have shown that starting ART earlier is associated with longer survival [17] [18] [19] [20] . Second, we review studies that evaluate strategies that reduce severe ART-related toxicities [21, 22] . Finally, we discuss studies that compare different strategies for monitoring ART efficacy and we examine several criteria for switching to second-line regimens when they are available.
Review of recent studies on the costeffectiveness of antiretroviral therapy
We used the Medline and AIDSLINE online databases to conduct a literature search of articles published between January 2006 and October 2009. We then reviewed citation and reference lists to identify additional studies. Table 1 provides a summary of the results and describes the methodological features of each analysis that evaluates the cost-effectiveness of ART in resource-limited settings.
Although there is no clearly defined threshold at which any health intervention can be considered 'cost effective', the guidelines of the WHO Commission on Macroeconomics and Health can be used to establish the comparative value of alternative interventions in a given country, taking into account its ability to pay for goods and services [31] . According to these guidelines, a strategy is considered cost effective if the incremental cost-effectiveness ratio (ICER) is below three times the annual per capita gross domestic product (GDP) of the country and very cost effective if the ICER is below one times the annual per capita GDP.
Cost-effectiveness of antiretroviral therapy: when to start antiretroviral therapy
The WHO recently updated its 2006 guidelines, entitled 'Antiretroviral therapy for HIV infection in adults and adolescents', using emerging evidence on the optimal timing of ART initiation and new drug regimens [16 ,32] . The guidelines outline the standard of care for HIVinfected people, while taking into account the risks and benefits, acceptability, feasibility, cost and financial implications of various treatment strategies. The guidelines strongly recommend starting ART at WHO clinical stage 3 or 4 irrespective of CD4 cell count, or at CD4 cell counts below 350 cells/ml irrespective of clinical symptoms. These recommendations are based on recent clinical data from cohort studies suggesting that early initiation reduces morbidity and mortality [17] [18] [19] [20] 33] . These higher thresholds will increase the number of eligible patients as well as affect overall costs. The value for the additional money spent, or cost-effectiveness, of earlier initiation must be assessed in order to determine its economic consequences.
Treatment tends to become less cost effective (ICERs increase) as CD4 cell counts at ART initiation increase. Using retrospective observational data from a Moroccan hospital, Loubiè re et al. showed that treatment was very cost effective when patients initiated ART at CD4 cell counts below 200 cells/ml (Morocco 2008 per capita GDP: US$2570 [34] ) [14 ] . Additional analyses were carried out to check cost-effectiveness beyond the CD4 cell count threshold of 200 cells/ml. The ICER increased to more than three times GDP per capita when the threshold for treatment initiation was increased to 350 cells/ml, whereas above this threshold the ICER was no longer cost effective. Badri et al. used data from the Cape Town AIDS Cohort study and found that initiating ART at CD4 cell counts above 350 cells/ml produced an ICER of US$1330 per quality-adjusted life year (QALY) gained compared with initiating ART at CD4 cell counts 200-350 cells/ml, which is less than the South African GDP per capita (South Africa 2008 per capita GDP, US$6190 [34] ) [11] . The latter strategy was associated with a lower ICER of US$720/ QALY compared with initiating ART at CD4 cell counts below 200 cells/ml.
In line with these studies, most research conducted in resource-limited settings suggests that ART initiation at CD4 cell counts below 350 cells/ml can easily be made cost effective with appropriate reductions in prices of major inputs such as antiretroviral drugs [10, 11, 13, 15 ]. In these studies, ICERs were most sensitive to the cost of ART. In Morocco, treatment was very cost effective when public sector ART costs were halved [14 ] . In South Africa, Badri et al. found that if ART costs were reduced by 40%, treatment was cost-saving compared with no ART, regardless of CD4 cell count at initiation [11] . Given these findings, mechanisms should be developed to assure long-term supplies of antiretroviral drugs at affordable costs, especially if HIV diagnoses occur increasingly early in the course of disease as a result of the successful expansion of HIV testing, and a growing number of patients begin switching to costlier secondline regimens.
Although earlier ART initiation is cost effective in many resource-limited settings, the benefits of treatment will only provide good value if rates of adherence and retention in care are high. In a recent study, Anglaret et al. [35] used a simulation model of HIV to demonstrate that early ART improves survival, except when adherence and retention are lower among patients starting ART earlier.
Although this study did not consider costs, it is likely that rates of adherence, adverse events, and loss to follow-up will affect the cost-effectiveness of ART.
Cost-effectiveness of antiretroviral therapy: what to start with
Even when patients are virologically suppressed on ART, they are susceptible to both drug resistance and toxicity [36] . Management of resistance and toxicity over time will emerge as a significant challenge in the fight against disease progression in both low-and high-income countries [37] [38] [39] .
Serious toxicities not only induce deterioration of patients' quality of life and additional medical and social costs [40] , they also increase the risk of loss to follow-up which can lead to drug resistance. Guidelines should be revised regularly to incorporate new data on ART-related adverse events and recommend drugs with lower toxicity profiles. In Africa, guidelines are frequently not followed due to financial reasons. For example, although the WHO recommends regimens containing either tenofovir or zidovudine, most first-line ART regimens continue to include stavudine despite the well known association of stavudine with long-term side-effects such as mitochondrial toxicity and dyslipidemia [41] [42] [43] [44] .
Several studies have evaluated the cost-effectiveness of first-line regimens containing alternative drugs in low and middle-income countries. Rosen et al. [23 ] recently showed that adding tenofovir to an initial regimen containing lamivudine or emtricitabine is cost effective over a 2-year period at the current cost of tenofovir in South Africa. The increased cost of tenofovir was offset by the cost of managing stavudine-related toxicities. The tenofovir strategy was then found very cost effective with modest reductions in cost (from US$18/month to US$13/month).
Bender et al. [24 ] evaluated the clinical outcomes, cost, and cost-effectiveness of four first-line ART regimens in India: stavudine-containing ART; stavudine-containing ART, followed by substitution of stavudine with zidovudine after 6 months to reduce the risk of lipodystrophy and lactic acidosis; zidovudine-containing ART; and tenofovir-containing ART. When the current cost of tenofovir-containing ART (US$16/month) was used, initiating ART with tenofovir, lamivudine and nevirapine was associated with an ICER of US$750/YLS compared with no ART (India 2008 per capita GDP, US$1090 [34] ). Alternative strategies were less cost effective. Both stavudine and zidovudine resulted in lower life expectancies than tenofovir, likely because the higher rates of virologic suppression and lower rates of toxicity associated with tenofovir reduced the probability of switching to a second-line regimen, thus making the tenofovir regimen more durable. These studies, as well as evidence that drug toxicities reduce treatment efficacy, strongly support the WHO' s guidelines revision to phase out stavudine in favor of initial regimens containing tenofovir or zidovudine.
Cost-effectiveness of antiretroviral therapy: what to switch to based on what criteria
As an increasing number of HIV-infected patients initiate ART in low-and middle-income settings and studies of drug resistance and interruptions in ART roll-out grow, decision-makers and national HIV/AIDS programs need robust information on the cost and clinical outcomes associated with long-term HIV care. Particularly in the context of resource constraints, evaluations of the costeffectiveness of first-, second-and then third-line ART regimens are critical. Furthermore, different strategies for monitoring ART efficacy must be assessed.
Most CEAs in resource-limited settings have compared single lines of ART, although second-line regimens have been considered in sensitivity analysis [10, 13, 45, 46] . Most studies found that adding a second-line regimen after failure of the first-line regimen increases both life expectancy and costs, but is not cost effective given the high costs of second-line therapy. If the cost of secondline ART decreases, however, this strategy would become of good value.
Some authors have assessed the cost-effectiveness of various sequences of ART regimens. Using a simulation model of HIV, Walensky et al. [25] evaluated the outcomes associated with a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen and a boosted protease inhibitor-based regimen administered in alternative orders. The study consistently favored initiation with an NNRTI-based regimen, regardless of the population prevalence of NNRTI resistance (up to 76%) and the efficacy of NNRTI-based ART. The most influential parameters were the cost and efficacy of the boosted protease inhibitor-based regimen.
Bendavid et al.
[26 ] recently compared two three-regimen strategies using cost and effectiveness data from South Africa: three nucleoside reverse transcriptase inhibitors (NRTIs), two NRTIs and one NNRTI, and two NRTIs and one boosted protease inhibitor; and two NRTIs and one NNRTI, two NRTIs and one boosted protease inhibitor, and a regimen containing a secondgeneration boosted protease inhibitor, such as ritonavirboosted darunavir. The authors concluded that initiating ART with three NRTIs is not cost effective. The second strategy was cost effective when CD4 cell count monitoring was available. HIV RNA monitoring was cost effective in countries with annual per capita GDP above US$2070. The 2009 WHO guidelines recommend that national programs establish standard third-line ART regimens containing new drugs such as integrase inhibitors and second-generation NNRTIs and protease inhibitors that have proven effective in treatment-experienced patients [16 ] .
In many resource-limited countries, CD4 cell count and HIV RNA tests are not routinely available, and their use has been the subject of considerable international debate [27 ,47,48] . Several studies have examined whether investments in CD4 cell count and HIV RNA tests are economically justifiable. These studies demonstrated that CD4 cell count monitoring was cost effective when compared with a symptom-based approach for determining the timing of treatment initiation. Furthermore, CD4 cell count tests benefited a substantial proportion of individuals for whom treatment would otherwise have been delayed until the appearance of life-threatening symptoms [10, 29 ] .
Studies on the use of laboratory monitoring, particularly virologic monitoring, to determine when to switch regimens have been less consistent. Phillips et al. [27 ] stated that the benefits of HIV RNA and/or CD4 cell count tests over clinical monitoring alone for switching therapy were modest. Others found that HIV RNA monitoring led to considerable benefits in low-income countries, but that this strategy was associated with high ICERs (US$16 520/ QALY in Bishai et al.; US$5610/YLS and US$105 000/ YLS when testing every 6 and 3 months, respectively, in Bendavid et al.) [28, 29 ] . Kimmel et al. [30 ] , in a study using data from Cô te d'Ivoire, recently found that HIV RNA tests were associated with favorable ICERs when used to guide the timing of ART switches. They estimated that at an HIV RNA test cost of US$98, US$56, and US$28, the ICERs of biannual HIV RNA tests were US$3290, US$2570, and US$2240/YLS, respectively (Cô te d'Ivoire 2008 per capita GDP: US$1120 [34] ) [30 ] . The results of these studies are not always consistent with each other, due to differences in model structure and input variables. The cost of the test, first-line ART efficacy, and the impact of resistance on the efficacy of second-line ART had an impact on costeffectiveness, but nearly all studies showed that the costeffectiveness of HIV RNA monitoring was more attractive when the cost of second-line treatment decreased. The new WHO guidelines recommend the use of HIV RNA tests, when available, to confirm treatment failure [16 ] . When HIV RNA tests are routinely available, they should be used to detect viral replication every 6 months. When they are not available, immunological criteria should be used to confirm clinical failure.
Conclusion
Many studies have now assessed the cost-effectiveness of HIV treatment in resource-limited settings. It is difficult to compare the results directly, because choice of time horizon, design, incorporation of the public health effects of ART in decreasing transmission, and costs differ among these studies. In order to provide information that is both clinically useful and policy-relevant, CEAs must be up-to-date, relevant to local settings, and available and understandable to decision-makers. Studies that reflect the most current understanding of HIV epidemiology and treatment should be continually refined and updated.
The studies described in this article report several important results. First, earlier ART initiation, based on CD4 criteria, is cost effective in most countries. Second, the high cost of first-line tenofovir-based ART may be offset by lower rates of long-term toxicity compared with first-line stavudine-based ART as well as by its decreasing cost over time. Third, HIV RNA monitoring combined with CD4 cell count monitoring is more clinically effective than CD4 cell count monitoring alone, but this strategy is not cost effective in all studies because HIV RNA tests and second-line regimens are often costly. Finally, third-line ART containing a secondgeneration boosted protease inhibitor may be cost effective. Further work is needed to determine the optimal sequence of ART regimens in terms of both survival and cost, the long-term consequences of alternative laboratory monitoring strategies, and the feasibility of incorporating these strategies into HIV/AIDS programs in low-and middle-income settings.
